Charles River Laboratories Signs Licensing Agreement with Luminex(R) Corporation
06 January 2006 - 6:47AM
Business Wire
Charles River Laboratories International, Inc. (NYSE:CRL) (Charles
River), a global provider of solutions that advance the drug
discovery and development process, and Luminex Corporation (NASDAQ:
LMNX) today announced that they have entered into a licensing
agreement whereby Charles River will utilize Luminex's xMAP(R)
technology within Charles River's Research Models and Services
business segment. The Luminex xMAP technology enables multiple
assays to be performed in a single well, or multiplexed, utilizing
suspended microspheres or beads. Up to 100 different simultaneous
assays can be performed in a single microtiter well, both rapidly
and precisely. Charles River's Research Animal Diagnostic Services
division will use the technology to create the Multiplexed
Fluorometric ImmunoAssay (MFIA), which will be adopted as the
platform for screening laboratory animal serum samples for
infectious disease. William Barbo, Charles River Laboratories
Corporate Vice President, Research Model Services, said, "Charles
River is pleased to join Luminex in this licensing agreement. The
use of Luminex's xMAP technology in the form of MFIA will allow us
the flexibility to further refine and expand our assays, delivering
unparalleled products and services in the area of laboratory animal
diagnostics." Russell Bradley, Vice President of Business
Development and Strategic Planning, Luminex Corporation, said, "We
are pleased Charles River Laboratories has selected our xMAP
technology as their multiplex platform of choice for the
standardization of animal diagnostic assays. As a market leader,
Charles River Laboratories joins a growing team of Luminex partners
bringing the benefits of Luminex's bead based multiplexing to their
customers." About Charles River Laboratories Charles River
Laboratories, based in Wilmington, Massachusetts, U.S., is a global
provider of solutions that advance the drug discovery and
development process. Our leading-edge products and services are
designed to enable our clients to bring drugs to market faster and
more efficiently. Backed by our rigorous, best-in-class procedures
and our proven data collection, analysis and reporting
capabilities, our products and services are organized into three
categories spanning every step of the drug development pipeline:
Research Models and Services, Preclinical Services, and Clinical
Services. Charles River's customer base includes all of the major
pharmaceutical companies and many biotechnology companies,
government agencies and leading hospitals and academic
institutions. Charles River's 8,400 employees serve clients in more
than 50 countries. For more information on Charles River, visit our
website at www.criver.com. About Luminex(R) Corporation Luminex
Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
life sciences industry. The Company's xMAP system is an
open-architecture, multi-analyte technology platform that delivers
fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and
biomedical research, including the genomics and proteomics research
markets. The Company's xMAP technology is sold worldwide and is in
use in leading research laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies. Luminex's
xMAP technology received the 2005 Clinical Diagnostics Technology
of the Year Award from Frost & Sullivan. Further information on
Luminex Corporation or xMAP can be obtained on the Internet at
http://www.luminexcorp.com or you may contact Harriss T. Currie,
Chief Financial Officer of Luminex Corporation, +1-512-219-8020.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Charles River Laboratories International, Inc. News Articles